Effects of herceptin on the serum tumor markers in patients with HER-2 positive advanced breast cancer treated with chemotherapy and its influence on the immune function
10.3760/cma.j.issn.1008-6315.2017.08.019
- VernacularTitle:注射用曲妥珠单抗对人表皮生长因子受体2阳性晚期乳腺癌化疗患者血清肿瘤标志物及免疫功能的影响
- Author:
Yuqin HUANG
- Keywords:
Herceptin;
Breast cancer;
Immune function;
Efficacy
- From:
Clinical Medicine of China
2017;33(8):748-752
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the effects of herceptin on the serum tumor markers in patients with HER-2 positive advanced breast cancer treated with chemotherapy and its influence on the immune function.Methods Seventy-six patients with HER2-positive advanced breast cancer from January 2013 to June 2014 in Xiangyang No.1 People's Hospital Affiliated to Hubei University of Medicine were divided into the observation group (38 cases) and the control group (38 cases),fifty healthy subjects in the same period were selected as the blank group.The control group received gemcitabine combined with capecitabine,gemcitabine 1000 mg / m2 via intravenous infusion in the first and eighth day,capecitabine 2500 mg/m2 via intravenous drip from the first day to fourteenth day;the observation group were given trastuzumab on the basis of the control group,4 mg/kg for the first time,then 2 mg/kg,1 time/week,three weeks for a course,have been given for four courses.The peripheral blood lymphocyte subsets were detected by flow cytometry,the Carcinoembryonic antigen (CEA),cancer-associated glycoprotein antigen (CA153) and tissue polypeptide specific antigen (TPS) were detected by enzyme-linked immunoassay.The short-term efficacy,survival and adverse reactions incidence rate in the two groups were compared.Results (1) The clinical benefit rate of the observation group was higher than that of the control group (89.47% vs.63.15%,χ2=8.508,P<0.05),the 1-year survival rate of the observation group was 65.79%,the control group was 39.47%,the difference was statistically significant (χ2=5.278,P<0.05),the 2-year survival rate of the observation group was 42.11%,the control group was 21.05%,the difference was statistically significant (χ2=3.897,P<0.05).(2) The CD3+,CD4+ and CD4+/CD8+ of the observation group and the control group after treatment were (51.5±5.2)%,(52.7±4.4)%,(24.1±5.6)%,(26.7±5.0)%,(0.81±0.10),(0.86±0.13),respectively,which were lower than those collected before treatment (t=5.734,4.824,6.056,5.428,3.602,3.643,P<0.05)),there were no significant differences in lymphocyte subset between the observation group and the control group before and after treatment (P>0.05),the CD3+,CD4+,CD4+/CD8+ of the observation group and the control group after treatment were significantly lower than those of the blank group (F=14.484,9.371,8.213,P<0.01).(3) The CEA,CA153 and TPS of the observation group and the control group after treatment were (5.05±2.03) μg/L,(7.25±2.70)μg/L,(36.04±12.05) IU/ml,(55.42±18.23) IU/ml,(262.43±53.38) IU/ml,(355.21±47.80) IU/ml,which were significantly lower than those before treatment (t=8.743,3.805,7.929,5.271,9.512,6.389,P<0.05),the observation group was significantly lower than the control group (t=3.353、3.665、3.442,P<0.05).(4) The incidence rate of pain and fever in the observation group were 34.21% and 28.95%,respectively,which were significantly higher than those in the control group,the difference was statistically significant (χ2=15.683,12.862,P<0.01).Conclusion Trastuzumab can synergistically reduce the serum tumor marker content in the treatment of patients with HER 2-positive advanced breast cancer,effectively improve the short-term efficacy of conventional chemotherapy,extend the life span,without the cause of significant damage to the immune function,but it can significantly increase the incidence rate of pain and fever,so it is necessary to carry out targeted method to improve chemotherapy compliance.
